The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: Rate worries keep European stocks in check

Fri, 10th Feb 2023 16:55

(Alliance News) - Stock prices in London closed lower on Friday, as news that the UK managed to avert a recession failed to inspire equities, with interest rate worries hanging over markets again.

"I think it's safe to say the sparkling wine can remain on ice after data this morning confirmed the UK avoided a recession at the end of 2022 by the narrowest of margins. So much so that there's every chance that a tiny revision over the next couple of months confirms quite the opposite," Oanda analyst Craig Erlam commented.

"Ultimately, this isn't a story of whether the UK is in recession or not as that's just a simple technical definition. It's a story of zero growth - quite literally in the case of the fourth quarter - and the fact that this likely represents the recent past, present, and near-term future prospects for the UK economy. High but falling inflation and basically no growth for some time. It's all a bit bleak really."

The FTSE 100 index closed down 28.70 points, or 0.4%, at 7,882.45. London's blue-chip benchmark achieved a record high on Thursday, but is ultimately 0.2% lower than it was last Friday.

The FTSE 250 closed down 247.27 points, or 1.2%, at 20,030.07, and the AIM All-Share ended down 6.45 points, or 0.7%, at 874.39.

For the week, the FTSE 250 slipped 2.7% and the AIM All-Share lost 1.7%.

The Cboe UK 100 closed down 0.5% at 788.29, the Cboe UK 250 lost 1.4% to 17,466.59, and the Cboe Small Companies ended down 0.3% at 14,097.73.

In European equities on Friday, the CAC 40 in Paris closed down 0.8%, while the DAX 40 in Frankfurt slumped 1.4%.

Oanda analyst Erlam added: "Central bankers, particularly from the Fed, have been out in force stressing caution over interest rate expectations.

"Markets are now pricing in two more hikes from the Fed and possibly one cut later in the year."

The dollar was stronger as the week draws to a close. The pound bought USD1.2072 at the time of the London equities close on Friday, down from USD1.2154 at the same time on Thursday. The euro stood at USD1.0677, lower against USD1.0750. Against the yen, the dollar was trading at JPY131.44, higher compared to JPY131.10.

According to a first estimate from the Office for National Statistics, UK gross domestic product saw no growth in the fourth quarter from the third. This follows a revised contraction of 0.2% in the third quarter from the second.

It means the UK avoided a technical recession, which is defined as two consecutive quarters of economic shrinkage.

The outlook for the UK economy is anything but promising, however, hitting sterling.

In London, share price gains for Shell and BP, on the back of rising Brent prices, prevented the FTSE 100 from suffering an even worse fall on Friday. Shell added 3.0% and BP rose 2.6%.

Brent oil was quoted at USD86.41 late Friday in London, up from USD83.73 late Thursday.

Russia announced Friday it will slash crude oil output by 5% next month after Western countries imposed a price cap over the Ukraine conflict.

International crude prices surged after Deputy Prime Minister Alexander Novak said that Russia would "voluntarily" reduce production by 500,000 barrels per day in March.

SPI Asset Management analyst Stephen Innes commented: "Novak certainly feels the pulse of the oil markets as the intervention comes on the heels of the street's biggest bull (Goldman Sachs) downgrading their 2023 forecast, ironically because of more supply coming from Russia than expected.

"Despite the intervention, there is a good chance we have seen the high oil price in H1 due to significantly increasing US recession odds and a far more hawkish Fed than expected. Given China's lack of organic growth, signalling a slower consumption recovery, it is doubtful we will get that slingshot rebound in Q2. We now see Brent trading back to USD78 [a barrel] in Q1 before rising to USD82 in Q2 as balances get tighter."

Back in London, AstraZeneca extended gains, rising 1.8% and helping the FTSE 100 avoid suffering a bigger fall at the end of the week. The stock had closed up 4.1% on Thursday.

Weighing on the index, however, Standard Chartered lost 5.0% as First Abu Dhabi Bank repeated that it has no plans to make a takeover offer for the lender.

FAB said on Friday that its stance had not changed since early last month, when it said it ended "very early stages" of evaluating a possible offer for StanChart.

Wealth managers also hurt the index, with abrdn sliding 4.0%, St James's Place losing 2.3% and M&G declining 2.2%.

HSBC predicted a tough outlook for the sector. It cut abrdn to 'reduce' but maintained the 'hold' and 'buy' ratings for St James's and M&G, respectively.

Elsewhere in London, Itim plunged 20% after it said annual earnings will fall short of market expectations.

The London-based click-and-collect software firm said earnings before interest, tax, depreciation and amortisation are expected to be GBP200,000 below current market expectations, at about GBP200,000, collapsing by more than 90% from GBP2.2 million in 2021.

Itim said this was due to its increased cost base after self-financing its projects to drive growth, offering transitions to its platform free of charge.

Stocks in New York were mixed at the time of the closing bell in London on Friday. The Dow Jones Industrial Average was up 0.3%, the S&P 500 index edged up 0.1%, though the Nasdaq Composite was down 0.6%.

Eyes were on the US bond markets on Friday, as the inversion of the treasury yield curve deepened on Thursday. The 10-year bond traded at a 3.73% yield around 1630 GMT, the five-year a 3.92% yield and the two-year at a 4.51% yield.

A normal yield curve would show that bonds with a longer maturity offer higher yields, while instruments with shorter maturity offer less chunky rewards. The opposite is true with an inverted yield curve - shorter-dated bonds pay more than those with a longer maturity.

SPI's Innes commented: "Indeed, the yield curve inversions are scaring bulls back to the pen, while new-year hibernating bears are stirring again. The [two to 10] treasury yield curve inverted by 85 basis points, the deepest inversion since the early 1980s, is waving multiple red flags about economic dangers just as investors price in a more hawkish Federal Reserve."

Gold was quoted at USD1,858.39 an ounce late Friday, lower against USD1,873.46 on Thursday.

In a quiet economic calendar on Monday, Federal Reserve Governor Michelle Bowman speaks at 1300 GMT.

The week picks up pace with eurozone GDP and unemployment readings on Tuesday, US inflation later that day, before UK consumer price index on Wednesday.

By Eric Cunha, Alliance News news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.